Third member of US FDA advisory panel resigns over Alzheimer's drug approval

Third member of US FDA advisory panel resigns over Alzheimer's drug approval

A third member of a panel of outside advisers to the US Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.

Continue reading at www.channelnewsasia.com